Search results for "Real-life"

showing 10 items of 28 documents

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

2016

AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician' s global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database. RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the averag…

AdultMalemedicine.medical_specialtyTime FactorsAnti-Inflammatory AgentsObservational StudySeverity of Illness IndexGolimumab03 medical and health sciences0302 clinical medicineGastrointestinal AgentsAdrenal Cortex HormonesInternal medicineHumansMedicineProspective StudiesTumor Necrosis Factor-alphabusiness.industryRemission InductionGastroenterologyAntibodies MonoclonalColonoscopyGeneral MedicineMiddle Agedmedicine.diseaseReal-life resultsUlcerative colitisdigestive system diseasesGolimumabTreatment OutcomeMulticenter studyUlcerative colitisSpain030220 oncology & carcinogenesisColitis UlcerativeDrug Therapy CombinationFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct

Inhalation therapy in the next decade

2018

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyRespiratory TherapyEuropean Seminars in Respiratory MedicineCost-Benefit Analysiseducationlcsh:MedicineMedication adherenceSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD; European Seminars in Respiratory Medicine; Inhalation therapyINSPIRATORY FLOW-RATEHistory 21st CenturyOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructivePATIENT ADHERENCECOPD; European Seminars in Respiratory Medicine; Inhalation therapy; Pulmonary and Respiratory MedicineITALIAN GENERAL-PRACTITIONERSmedicinePulmonary MedicineHumansCOPDMortalityMEDICATION ADHERENCEIntensive care medicineAsthmaHEALTH-CARE PROFESSIONALSCOPDInhalationbusiness.industryDRY POWDER INHALERlcsh:ROBJECTIVELY IDENTIFIED COMORBIDITIESIMPROVES LUNG-FUNCTIONHistory 20th Centurymedicine.diseaseDry-powder inhalerAsthmarespiratory tract diseasesRespiratory MedicineREAL-LIFEItalyInhalation therapyFemaleCardiology and Cardiovascular MedicinebusinessMonaldi Archives for Chest Disease
researchProduct

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study a…

2017

Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of pa…

randomized controlled trial; real-life; retrospective study; sodium glucose co-transporter-2 inhibitor; medicine (miscellaneous); endocrinology; diabetes and metabolism; nutrition and dietetics; cardiology and cardiovascular medicineBlood GlucoseTime FactorsGlucosideGlycated Hemoglobin ATime FactorMedicine (miscellaneous)Settore MED/13 - EndocrinologiaEndocrinologyGlucosidesSodium-Glucose Transporter 2Retrospective StudieDiabetes MellitusHumansHypoglycemic AgentsData MiningBenzhydryl CompoundsRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSodium-Glucose Transporter 2 InhibitorsRetrospective StudiesGlycated HemoglobinBenzhydryl CompoundNutrition and DieteticsEvidence-Based MedicineHypoglycemic AgentSodium-Glucose Transporter 2 InhibitorRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based MedicineReal-lifeBiomarkerDiabetes and MetabolismRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineRetrospective studyTreatment OutcomeDiabetes Mellitus Type 2ItalyRandomized controlled trialResearch DesignSodium glucose co-transporter-2 inhibitorCrowdsourcingCardiology and Cardiovascular MedicineBiomarkersType 2Human
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

2016

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care p…

PediatricsAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis; Immunology and AllergyIMPACTHay feverRespiratory Medicine and AllergyDiseaseReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineQUALITY-OF-LIFEHDE ALERHealth careMedicine and Health SciencesPERSISTENT ALLERGIC RHINITISMedicineImmunology and Allergy030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAIRWAYS ICPComputingMilieux_MISCELLANEOUSRhinitiAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; RhinitisLungmedicin och allergiRhinitisPublic Health Global Health Social Medicine and Epidemiology3. Good healthREAL-LIFEAIRWAYS ICPsARIA; Rhinitis; ICT; EIP on AHA; Mobile technology; AIRWAYS ICPsHay feverCLINICAL-PRACTICE GUIDELINESHEALTHPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAEUROPEAN INNOVATION PARTNERSHIPImmunologySocio-culturaleClinical decision support systemICT; EIP on AHAPredictive medicine03 medical and health sciencesQuality of life (healthcare)Mobile technologyJournal ArticleMobile technologyAsmaAsthmaScience & TechnologyARIAbusiness.industryAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis;Settore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSCorrectionmedicine.disease2008 UPDATEFebre del fencAsthmaFolkhälsovetenskap global hälsa socialmedicin och epidemiologi030228 respiratory systemFamily medicineICTVISUAL ANALOG SCALEbusiness
researchProduct

The mixed capacitated general routing problem with turn penalties

2011

In this paper we deal with the mixed capacitated general routing problem with turn penalties. This problem generalizes many important arc and node routing problems, and it takes into account turn penalties and forbidden turns, which are crucial in many real-life applications, such as mail delivery, waste collection and street maintenance operations. Through a polynomial transformation of the considered problem into a Generalized Vehicle routing problem, we suggest a new approach for solving this new problem by transforming it into an Asymmetric Capacitated Vehicle routing problem. In this way, we can solve the new problem both optimally and heuristically using existing algorithms. A powerfu…

Capacitated vehicle routing problemMathematical optimizationRouting problemsPolynomial transformationReal-life applicationsTurn penaltiesCapacitated general routing problemRouting algorithmsVehicle Routing ProblemsTransformationPolynomial transformationsArtificial IntelligenceVehicle routing problemDestination-Sequenced Distance Vector routingGeneral routing problemMathematicsta113Average deviationStatic routingWaste collectionNode (networking)General EngineeringSolution methodsMaintenance operationsVehicle routingComputer Science ApplicationsMemetic algorithmsBenchmark (computing)Network routingMemetic algorithmRouting (electronic design automation)MATEMATICA APLICADAAlgorithmsExpert Systems with Applications
researchProduct